^
    1m
    A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (clinicaltrials.gov)
    P1/2, N=240, Recruiting, Pfizer | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HR positive + HER-2 positive • PTEN mutation + HR positive
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060) • tagtociclib (PF-07104091)
    1m
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1/2, N=337, Recruiting, Pfizer | Trial completion date: Oct 2027 --> May 2028 | Trial primary completion date: Aug 2026 --> Mar 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification • HR positive + HER-2 negative • HR positive + HER-2 positive • PTEN mutation + HR positive
    |
    Xtandi (enzalutamide capsule) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride
    2ms
    A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    atirmociclib (PF-07220060)
    2ms
    A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Nov 2026 --> Feb 2026 | Trial primary completion date: May 2026 --> Aug 2025
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    vepdegestrant (ARV-471) • atirmociclib (PF-07220060)
    2ms
    A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (clinicaltrials.gov)
    P3, N=510, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    everolimus • fulvestrant • exemestane • atirmociclib (PF-07220060)
    3ms
    A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults (clinicaltrials.gov)
    P1, N=12, Recruiting, Pfizer
    New P1 trial
    |
    atirmociclib (PF-07220060)
    4ms
    A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (clinicaltrials.gov)
    P1/2, N=65, Not yet recruiting, Pfizer
    New P1/2 trial • Combination therapy • Metastases
    |
    vepdegestrant (ARV-471) • atirmociclib (PF-07220060)
    6ms
    A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (clinicaltrials.gov)
    P1/2, N=240, Recruiting, Pfizer | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060) • tagtociclib (PF-07104091)
    6ms
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1/2, N=337, Recruiting, Pfizer | Trial completion date: Feb 2026 --> Sep 2027 | Trial primary completion date: Feb 2026 --> Jul 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    Xtandi (enzalutamide capsule) • fulvestrant • letrozole • atirmociclib (PF-07220060)
    6ms
    A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (clinicaltrials.gov)
    P3, N=510, Not yet recruiting, Pfizer
    New P3 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    everolimus • fulvestrant • exemestane • atirmociclib (PF-07220060)
    7ms
    A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (clinicaltrials.gov)
    P1b/2, N=240, Recruiting, Pfizer | N=144 --> 240
    Enrollment change • Combination therapy • Metastases
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060) • tagtociclib (PF-07104091)
    10ms
    A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (clinicaltrials.gov)
    P1b/2, N=144, Recruiting, Pfizer | Trial completion date: Jul 2027 --> Sep 2026
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060) • tagtociclib (PF-07104091)
    almost1year
    A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (clinicaltrials.gov)
    P1b/2, N=144, Recruiting, Pfizer | Trial completion date: Dec 2027 --> Jul 2027 | Trial primary completion date: Dec 2026 --> Jul 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060) • tagtociclib (PF-07104091)
    almost1year
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1/2, N=337, Recruiting, Pfizer | N=198 --> 337
    Enrollment change • Combination therapy • Metastases
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    Xtandi (enzalutamide capsule) • fulvestrant • letrozole • atirmociclib (PF-07220060)
    1year
    First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy. (ASCO 2023)
    At data cut off (Nov 1, 2022), 34 pts with advanced solid tumors received PF-07220060 in monotherapy dose escalation (Part 1A: 100–500 mg BID), and 26 pts with HR+/HER2- mBC in combination (300mg/400mg BID) with letrozole or fulvestrant (Parts 1B + 1C). PF-07220060 + ET showed efficacy in pts with HR+/HER2- mBC who progressed on prior CDK4/6i+ET. Tolerability of PF-07220060 alone and in combination with ET was encouraging. Dose expansions with PF-07220060 + ET in pts with HR+/HER2- mBC post CDK4/6i and in CDK4/6i naïve pts are ongoing.
    Clinical • P1/2 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060)
    1year
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1/2, N=198, Recruiting, Pfizer | N=337 --> 198
    Enrollment change • Combination therapy • Metastases
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    Xtandi (enzalutamide capsule) • fulvestrant • letrozole • atirmociclib (PF-07220060)
    1year
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1/2, N=337, Recruiting, Pfizer | Phase classification: P1 --> P1/2 | N=118 --> 337 | Trial completion date: Apr 2025 --> Feb 2026 | Trial primary completion date: Apr 2025 --> Feb 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    Xtandi (enzalutamide capsule) • fulvestrant • letrozole • atirmociclib (PF-07220060)
    1year
    KAT6: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=186, Recruiting, Pfizer | Trial completion date: Sep 2027 --> Nov 2026 | Trial primary completion date: Apr 2026 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    ER positive • HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • PF-07248144 • atirmociclib (PF-07220060)
    1year
    KAT6: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=200, Recruiting, Pfizer | N=108 --> 200
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    ER positive • HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • PF-07248144 • atirmociclib (PF-07220060)
    over1year
    A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid Tumors (clinicaltrialsregister.eu)
    P2, N=144, Ongoing, Pfizer Inc.
    New P2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060) • tagtociclib (PF-07104091)
    over1year
    KAT6: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, Pfizer | Trial completion date: Oct 2025 --> Sep 2027 | Trial primary completion date: May 2024 --> Apr 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    ER positive • HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • PF-07248144 • atirmociclib (PF-07220060)
    over2years
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1, N=118, Recruiting, Pfizer | N=52 --> 118 | Trial completion date: Mar 2024 --> Apr 2025 | Trial primary completion date: Mar 2024 --> Apr 2025
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060)
    over3years
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1, N=52, Recruiting, Pfizer | Trial completion date: Sep 2024 --> May 2024 | Trial primary completion date: Sep 2024 --> May 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1)
    |
    HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060)
    over3years
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1, N=52, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1)
    |
    HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060)
    over3years
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, Pfizer
    Clinical • New P1 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1)
    |
    HR positive • HER-2 negative • CCND1 amplification • CDK4 amplification
    |
    fulvestrant • letrozole • atirmociclib (PF-07220060)